Deepak Nitrite's prospect continues to be driven by phenolics biz

Deepak Nitrite is seeing strong investor confidence with its stock prices more than doubling year to date. The company, which is an established manufacturer of phenol, acetone, and isopropyl alcohol through its subsidiary Deepak Phenolics, has continued to benefit from rising prices of phenol derivatives. 

Global supply disruption for these chemicals during the year benefitted the company. Having created India’s largest phenol-acetone plant, the company will continue to accrue benefits from the country’s growing demand and import substitutions. Being a basic manufacturer, it also has a good edge over cost competition.

While investment rationale remains strong, in the near term there will be challenges too. Prices of phenol seem to be peaking around current levels, while acetone prices have normalized from their peak over the last two months, said analysts at Motilal Oswal Financial Services post Q2 results. EBIT margin in fine and specialty chemicals dipped for the fourth consecutive quarter and the same for basic chemicals normalized, said analysts.

In the ongoing third quarter, prices continue to correct further. Recent chemical and petrochemical prices data by Emkay Global Financial Services indicates that prices of phenol and acetone in November are down 4.9% and 11.4% over October.

Thus, there may not be benefits from rising realisations. Also, the company had achieved its highest-ever plant utilization rate of 120% in 2QFY22, leaving limited growth in this segment for volume accretion, say analysts.

The longer-term prospects nevertheless remain strong and intact. Having fully integrated manufacturing facilities will help it manage and produce chemicals with a competitive advantage. Deepak Phenolics caters to several end-user industries such as agrochemicals, rubber, pharmaceuticals, paper, textile, detergent, colorants, paints, etc. resulting in a natural hedge, say analysts.

Analysts at JM Financial expect “Sales, Ebitda and Earnings per share to post 18%, 18%, and 20% CAGR (compound annual growth rate), respectively, over FY21-24E". Despite an aggressive capex of ₹1,500 crore over FY23-24, they expect its return on capital employed (pre-tax) to remain 32% over FY23E-24E.

Lincoln Pharma Promotors buying ☝️

SEBI approves National Stock Exchange ( NSE) IPO at 2 Lakh Cr valuation

If this is correct then the IPO is valued at FY21 P/E of 56x

NSE did revenues of Rs 5642crs & PAT of 3573crs in FY21

+ve for DEEPAK NITRITE

Phenol prices UP 37% MOM

Acetone Prices UP 32% MOM

DADSA prices almost stable

NIFTY HAS GIVEN 14 TIMES POSITIVE MOVES IN MONTH OD DECEMBER IN LAST 20 YEARS

Maximum people Buy Near Resistance instead of NEAR SUPPORT....

&

MAX people Sell Near SUPPORT instead of RESISTANCE .....

https://wealthcreatures.com/2020/06/15/magma-fincorp-dark-horse-for-longterm-can-it-again-cross-its-all-time-high-194/

✅ POONAWALA FINCORP ✅
(MAGMA FINCORP)

🔆Already Multibagger for Us
11x ( 1100% Returns )

18.50 To 211 🎯 Done Till ✔ Now

Cmp - 205.75

Next Test Levels # 15x/20×/25×/50× ++

Market Cap – Rs. 15762 Cr

No. of Shares – 76.46 Cr

Promotor Holding – 72.52%

FII’s and DII’s - 12.92%

Retail Holding – 14.56%

🔆 Recently, in an investor presentation, the company said it was aiming to be among Top
3 NBFCs for consumer and small/medium business finance.

🔆Company has financial backing from Adar Poonawalla, CEO of Serum Institute of India - world's largest manufacturer of vaccines.

🔆 Poonawala Fincorp can become bigger player in long run.In terms of stock price returns can give bigger Returns like Bajaj Finance in long term.

KOPRAN LTD

Board meeting on 8th Dec'21 to approve issue preferencial Equity shares to promotors Group & others

JEEVAN SCIENTIFIC

FRESH ATH

141 🎯💚

80 TO 141 DONE ✔ TILL NOW

Fresh Revised Test Levels # 155/166/189/200

Lomgterm - 333/450++

CLEAN SCIENCE

NOW UP 7% 💚

2660 🎯

1780 TO 2660 DONE ✔ TILL NOW

NEXT TEST LEVELS # 2727/3000/3333++


LONGTERM - 5500